|
Accueil > Actualité
Regeneron: buys rights to Libtayo from Sanofi
(CercleFinance.com) - On Thursday Sanofi announced that it has granted its US partner Regeneron exclusive worldwide licensing rights to the anti-cancer drug Libtayo.
Under the terms of the agreement, Regeneron will receive an upfront payment of 900 million dollars, plus royalties of 11% on worldwide net sales of the drug. Sanofi will also be eligible for a regulatory milestone payment of 100 million dollars, as well as sales-related payments of up to 100 million dollars over the next two years. The collaboration and licensing agreement between both groups in 2015 had previously provided for equal sharing of profits generated by Libtayo sales. While Sanofi and Regeneron jointly marketed the product in the US, Sanofi was solely responsible for marketing it elsewhere in the world. Copyright (c) 2022 CercleFinance.com. All rights reserved. |
31/03/2023 17:32
Pixiumle titre s'envole après une annonce de la FDA 31/03/2023 17:12 CRHnouveau rebond, un broker relève son objectif 31/03/2023 17:02 Enirenforce sa position dans le stockage du carbone 31/03/2023 16:54 BlackBerrytrimestre décevant, mais les objectifs rassurent 31/03/2023 16:30 Boeingle taïwanais EVA Air commande cinq 787 en plus 31/03/2023 16:01 SAPSabine Bendiek n'ira pas au-delà de son contrat Tous les articles sociétés |
